glp 1 brain inflammation GLP-1 and the Degenerating Brain: Exploring Mechanistic Insights and Therapeutic Potential GLP-1 programs the neurovascular landscape:

Here, we highlight the mechanisms linking T2DM and PD, as well as the links between insulin resistance (IR) and PD patients risk of developing cognitive deficits

At the same time, both Lilly and Novo Nordisk made multi-billion dollar capital investments in expanding their manufacturing capacity to satisfy unrelenting patient demand, including pharmas largest M&A deal of the year, the $16.5Bn acquisition of CDMO Catalent by Novo Holdings, the controlling shareholder of Novo Nordisk

Here we review published data from 24-h time-averaged HR monitoring in healthy individuals and subjects with type 2 diabetes mellitus (T2DM) treated with either short-acting GLP-1 RAs, lixisenatide or exenatide, or long-acting GLP-1 RAs, exenatide LAR, liraglutide, albiglutide, or dulaglutide (N = 1112

GLP-1 receptor agonist drugs like Ozempic slow emptying of the stomach and bowel, affecting colonoscopy and endoscopy prep.

Medical eligibility depends on BMI, metabolic health, and individual risk factors evaluated by a qualified provider.